Type of Arrangement and Non-arrangement Transactions [Axis]
Klarity License Agreement [Member]
Title of Individual [Axis]
Richard L. Lindstrom, M.D [Member]
Award Type [Axis]
Restricted Stock Units [Member]
Class of Warrant or Right [Axis]
Warrant [Member]
Related Party [Axis]
Surface Pharmaceuticals [Member]
Eton Pharmaceuticals [Member]
Sales and Marketing Agreements [Member]
Legal Entity [Axis]
Surface Pharmaceuticals Inc [Member]
Management Services Agreement [Member]
Class of Stock [Axis]
Surface Series A Stock [Member]
Equity Components [Axis]
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Range [Axis]
Maximum [Member]
Scenario [Axis]
Initial Payment [Member]
License Agreement [Member]
Second Payment [Member]
Final Payment [Member]
Dr. Lindstrom [Member]
Minimum [Member]
Settlement Agreement [Member]
Concentration Risk Type [Axis]
Three Main Suppliers [Member]
Stock Option Plan [Member]
Income Statement Location [Axis]
Research and Development Expense [Member]
Product and Service [Axis]
Product Sales, Net [Member]
License Revenues [Member]
Finite-Lived Intangible Assets by Major Class [Axis]
Patents [Member]
Licenses [Member]
Customer Relationships [Member]
Trade Name [Member]
Non-Competition Clause [Member]
State Pharmacy Licenses [Member]
Debt Instrument [Axis]
Note Payable [Member]
Options Granted to Employees [Member]
Exercise Price Range [Axis]
Range One [Member]
Range Two [Member]
Range Three [Member]
Range Four [Member]
Range Five [Member]
Lender Warrants [Member]
Settlement Warrants [Member]
PIPE Investor and Placement Agent Warrants [Member]
Lender Warrants One [Member]
Melt Pharmaceuticals [Member]
Total Harrow Health, Inc Equity [Member]
Total Noncontrolling Interest Equity [Member]
Elle Pharmaceutical, LLC [Member]
Consolidated Entities [Axis]
Parent Company [Member]
Eton Pharmaceuticals, Inc. [Member]
Melt Series A Stock [Member]
Melt Pharmaceuticals, Inc. [Member]
Option Indexed to Issuer's Equity, Type [Axis]
Stock Option [Member]
Management Services Agreement [Member]
Surface License Agreements [Member]
Trademarks [Member]
Notes Payable [Member]
Geographical [Axis]
San Diego [Member]
Irvine [Member]
Ledgewood [Member]
Lease Arrangement, Type [Axis]
Finance Leases [Member]
Common Stock Warrants [Member]
Common Stock Warrants One [Member]
Restricted Stock [Member]
Plan Name [Axis]
2017 Incentive Stock and Awards Plan [Member]
Stock Option Plan [Member]
Employees [Member]
Unvested RSUs [Member]
Mayfield Pharmaceuticals, Inc. [Member]
Selling, General and Administrative [Member]
Directors [Member]
Consultants [Member]
Pharmaceutical Compounding [Member]
Pharmaceutical Drug Development [Member]
Operating Lease [Member]
Financing Lease [Member]
2017 Plan [Member]
Subsequent Event Type [Axis]
Subsequent Event [Member]
Asset Purchase Agreement [Member]
Milestone Payment [Member]
Milestone Payment [Member]
Milestone Payment [Member]
Document And Entity Information
Entity Registrant Name
Entity Central Index Key
Document Type
Document Period End Date
Amendment Flag
Current Fiscal Year End Date
Entity Filer Category
Entity Small Business Flag
Entity Emerging Growth Company
Entity Ex Transition Period
Entity Common Stock, Shares Outstanding
Trading Symbol
Document Fiscal Period Focus
Document Fiscal Year Focus
Statement [Table]
Statement [Line Items]
ASSETS
Current assets
Cash and cash equivalents, including restricted cash of $200
Investment in Eton Pharmaceuticals
Accounts receivable, net
Inventories
Prepaid expenses and other current assets
Total current assets
Property, plant and equipment, net
Operating lease right-of-use assets
Intangible assets, net
Investment
Goodwill
TOTAL ASSETS
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities
Accounts payable and accrued expenses
Accrued payroll and related liabilities
Deferred revenue and customer deposits
Current portion of note payable, net of unamortized debt discount
Current portion of operating lease obligations
Current portion of finance lease obligations, net of unamortized discount
Total current liabilities
Operating lease obligations, net of current portion
Finance lease obligations, net of current portion and unamortized discount
Accrued expenses, net of current portion
Note payable, net of current portion and unamortized debt discount
TOTAL LIABILITIES
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY
Common stock, $0.001 par value, 50,000,000 shares authorized, 24,718,649 and 24,339,610 shares issued and outstanding at March 31, 2019 and December 31, 2018, respectively
Additional paid-in capital
Accumulated deficit
TOTAL HARROW HEALTH, INC. STOCKHOLDERS' EQUITY
Noncontrolling interests
TOTAL STOCKHOLDERS' EQUITY
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY
Statement of Financial Position [Abstract]
Restricted cash
Common stock, par value
Common stock, shares authorized
Common stock, shares issued
Common stock, shares outstanding
Revenues:
Total revenues
Cost of sales
Gross profit
Operating expenses:
Selling, general and administrative
Research and development
Total operating expenses
Loss from operations
Other income (expense):
Interest expense, net
Investment gain from and equity net Loss
Other income, net
Total other income (expense), net
Total net income (loss) including noncontrolling interests
Net loss attributable to noncontrolling interests
Net income (loss) attributable to Harrow Health, Inc.
Basic net income (loss) per share of common stock
Diluted net income (loss) per share of common stock
Weighted average number of shares of common stock outstanding, basic
Weighted average number of shares of common stock outstanding, diluted
Balance
Balance, shares
Issuance of common stock in connection with: Vesting of RSUs, net of tax withholding
Issuance of common stock in connection with: Vesting of RSUs, net of tax withholding, shares
Issuance of common stock in connection with: Sale of stock, net of costs (ATM)
Issuance of common stock in connection with: Sale of stock, net of costs (ATM), shares
Issuance of common stock in connection with: Stock-based payment for services provided
Issuance of common stock in connection with: Stock-based payment for services provided, shares
Stock-based compensation expense
Net income (loss)
Issuance of common stock in connection with: Exercise of warrants
Issuance of common stock in connection with: Exercise of warrants, shares
Balance
Balance, shares
CASH FLOWS FROM OPERATING ACTIVITIES
Net income (loss) (including noncontrolling interests)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization of property, plant and equipment
Amortization of intangible assets
Amortization of operating lease right-of-use assets
Amortization of debt issuance costs and discount
Investment gain from and equity in net loss
Gain on sale and disposal of assets
Stock-based payment of consulting services
Stock-based compensation
Changes in assets and liabilities:
Accounts receivable
Inventories
Prepaid expenses and other current assets
Accounts payable, accrued expenses and other liabilities
Accrued payroll and related liabilities
Deferred revenue and customer deposits
NET CASH USED IN OPERATING ACTIVITIES
CASH FLOWS FROM INVESTING ACTIVITIES
Repayment of note receivable
Proceeds on sale and disposal of assets
Investment in patent and trademark assets
Purchases of property, plant and equipment
NET CASH USED IN INVESTING ACTIVITIES
CASH FLOWS FROM FINANCING ACTIVITIES
Payments on finance lease obligations
Payments on Park deferred acquisition obligation
Principal payments on note payable
Net proceeds from ATM sales of common stock
Net proceeds from exercise of warrants
NET CASH USED IN FINANCING ACTIVITIES
NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, beginning of period
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of period
RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH
Cash and cash equivalents
Restricted cash
CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF PERIOD
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for income taxes
Cash paid for interest
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Issuance of common stock for consulting services, included in accounts payable and accrued expenses
Changes in accrued property and equipment purchases
Acquisition of property, plant and equipment with finance lease obligations
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business and Basis of Presentation
Accounting Policies [Abstract]
Summary of Significant Accounting Policies
Revenue from Contract with Customer [Abstract]
Revenues
Investments, Debt and Equity Securities [Abstract]
Investment in Melt Pharmaceuticals, Inc. and Agreements - Related Party Transactions
Investment in Surface Pharmaceuticals Inc. and Agreements - Related Party Transactions
Inventory Disclosure [Abstract]
Inventories
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expenses and Other Current Assets
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill
Payables and Accruals [Abstract]
Accounts Payable and Accrued Expenses
Debt Disclosure [Abstract]
Debt
Leases [Abstract]
Leases
Equity [Abstract]
Stockholders' Equity and Stock-Based Compensation
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies
Segment Reporting [Abstract]
Segment Information and Concentrations
Subsequent Events [Abstract]
Subsequent Events
Liquidity
Segments
Noncontrolling Interests
Basic and Diluted Net Income (Loss) Per Common Share
Investment in Eton Pharmaceuticals, Inc. - Related Party
Investment in Melt Pharmaceuticals, Inc. - Related Party
Investment in Surface Pharmaceuticals, Inc. - Related Party
Recently Adopted Accounting Pronouncements
Recently Issued Accounting Pronouncements
Schedule of Basic Earnings Per Common Share
Schedule of Diluted Common Equivalent Shares
Schedule of Diluted Earnings Per Common Share
Schedule of Disaggregated Revenue
Schedule of Condensed Income Statement
Schedule of Condensed Balance Sheet
Schedule of Inventories
Schedule of Prepaid Expenses and Other Current Assets
Schedule of Property, Plant and Equipment
Schedule of Intangible Assets
Schedule of Amortization Expenses for Intangible Assets
Schedule of Estimated Future Amortization Expense
Schedule of Accounts Payable and Accrued Expenses
Summary of Future Minimum Payments
Schedule of Future Lease Payment Under Operating Leases
Schedule of Future Lease Payment Under Finance Lease
Schedule of Future Minimum Lease Payments Under Operating Lease and Finance Lease
Schedule of Stock Option Plan Activity
Schedule of Fair Value Assumptions
Schedule of Stock Option Outstanding and Exercisable
Schedule of Restricted Stock Units Activity
Schedule of Warrants Activity
Schedule of Warrants Outstanding and Warrants Exercisable
Schedule of Stock Based Compensation Granted to Employees Directors Consultants
Segment Information And Concentrations Table
Schedule of Operating Segment
Number of shares issued
Ownership percentage
Voting rights, description
Loss from operations
Net cash used in operating activities
Cash resources and restricted investments, marketable securities
Number of segments
Non controlling interest description
Antidilutive securities
Number of shares vested during the period
Number of shares owned
Stock price per shares
Gain on investment
Fair market value of investments
Proceeds from issuance of preferred stock
Gain on deconsolidation amount
Net income (loss)
Carrying value of investments
Right of use asset
Lease liability
Denominator – weighted average number of shares outstanding, basic
Net income (loss) per share, basic
Dilutive common equivalent shares
Dilutive common equivalent shares
Number of shares used for diluted earnings per share computation
Net income (loss) per share, diluted
Total Revenues
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Royalty payment percentage on net sales
Administrative expenses
Reimbursable expenses due
Revenues, net
Current assets
Non current assets
Total assets
Total liabilities
Total stockholders' equity
Total liabilities and stockholders' equity
Royalty payment description
Raw materials
Work in progress
Finished goods
Total inventories
Prepaid insurance
Other prepaid expenses
Receivable due from related party
Deposits and other current assets
Total prepaid expenses and other current assets
Computer software and hardware
Furniture and equipment
Lab and pharmacy equipment
Leasehold improvements
Property, plant and equipment, gross
Accumulated depreciation and amortization
Property, plant and equipment, Net
Statistical Measurement [Axis]
Amortization periods (in years)
Amortization periods description
Cost
Accumulated amortization
Impairment
Net Carrying value
Remainder of 2019
2020
2021
2022
2023
Thereafter
Intangible assets
Accounts payable
Accrued litigation settlement (see Note 14)
Deferred rent
Accrued interest
Accrued exit fee for note payable
Total accounts payable and accrued expenses
Less: Current portion
Non-current total accrued expenses
Amortization of debt discount
Remainder of 2019
2020
2021
2022
Total minimum payments
Less: amount representing interest
Notes payable, gross
Less: unamortized discount
Notes payable
Less: current portion, net of unamortized discount
Note payable, net of current portion and unamortized debt discount
Operating lease space
Operating lease expires date
Lease term
Lease term description
Operating lease percentage
Operating weighted average remaining term
Operating lease right use of assets
Decrease in accounts payable and accrued expenses
Operating lease liability
Cash paid in operating lease liability
Operating lease expense
Debt discount amortization
Depreciation expenses
Cash paid for interest expenses
Remainder of 2019
2020
2021
2022
2023
Thereafter
Total minimum lease payments
Less: amount representing interest payments
Total operating lease liabilities
Less: current portion, operating lease liabilities
Operating lease liabilities, net of current portion
Remainder of 2019
2020
2021
2022
2023
Total minimum lease payments
Less: amount representing interest payments
Present value of future minimum lease payment
Present value of future net minimum lease payments
Less: current portion, net of unamortized discount
Finance lease obligation, net of current portion
2019
2020
2021
2022
2023
Thereafter
Financing lease payment
2019
2020
2021
2022
2023
Thereafter
Operating lease payment
Less: Amounts representing interest
Less: Amounts representing unamortized discount
Total obligation under capital leases
Less: Current portion of capital leases
Long term capital lease obligation
Shares issued of common stock, shares
Commission expense
Exercise of warrants, shares
Warrants exercise price
Number of shares issued, avlue
Maximum number of common stock issuance under the plan
Closing price of common stock price per share
Stock options granted with exercise price contractual terms
Stock options granted vesting terms
Forfeiture factor, percentage
Unrecognized compensation expense related to unvested stock options granted under the plan
Expense expected to recognize over the weighted-average remaining vesting period
Fair market value of restricted shares
Number of shares issued for acquisition
Number of shares, Outstanding, Beginning balance
Number of shares, Options granted
Number of shares, Options exercised
Number of shares, Options cancelled/forfeit
Number of shares, Outstanding, Ending balance
Number of shares, Options exercisable
Number of shares, Options vested and expected to vest
Weighted Avg. Exercise Price, Outstanding, Beginning balance
Weighted Avg. Exercise Price, Options granted
Weighted Avg. Exercise Price, Options exercised
Weighted Avg. Exercise Price, Options cancelled/forfeit
Weighted Avg. Exercise Price, Outstanding, Ending balance
Weighted Avg. Exercise Price, Exercisable Ending Balance
Weighted Avg. Exercise Price, Vested and expected to vest
Weighted Avg. Remaining Contractual Life, Options outstanding
Weighted Avg. Remaining Contractual Life, Options exercisable
Weighted Avg. Remaining Contractual Life, Options vested and expected to vest
Aggregate Intrinsic Value, Options outstanding
Aggregate Intrinsic Value, Options exercisable
Aggregate Intrinsic Value, Options vested and expected to vest
Weighted-average fair value of options granted
Expected terms (in years)
Expected volatility, minimum
Expected volatility, maximum
Risk-free interest rate, minimum
Risk-free interest rate, maximum
Dividend yield
Range of Exercise Prices, minimum
Range of Exercise Prices, maximum
Number of Options Outstanding
Weighted Average Remaining Contractual Life in Years
Weighted Average Exercise Price
Number Exercisable
Weighted Average Exercisable Exercise Price
Number of RSUs unvested, Outstanding, Beginning balance
Number of RSUs granted
Number of RSUs vested
Number RSUs cancelled/forfeit
Number of RSUs unvested, Outstanding, Ending balance
Weighted Average Grant Date Fair Value, Beginning balance
Weighted Average Grant Date Fair Value, RSUs granted
Weighted Average Grant Date Fair Value, RSUs vested
Weighted Average Grant Date Fair Value, Ending balance
Number of Shares Warrants Outstanding, beginning balance
Number of Shares Warrants Outstanding, Granted
Number of Shares Warrants Outstanding, Exercised
Number of Shares Warrants Outstanding, Expired
Number of Shares Warrants Outstanding, ending balance
Weighted average remaining contractual life of the outstanding warrants in years
Weighted avg. Exercise Price, outstanding, beginning balance
Weighted avg. Exercise Price, exercised
Weighted avg. Exercise Price, outstanding and exercisable, ending balance
Issue Date
Warrants Outstanding
Exercise Price
Expiration Date
Stock based compensation related to equity instruments granted to related parties
Damages in lawsuit
Accrued expenses
Royalty payments
Net sales
Commission payments, percentage
Stock based payments
Commission expense incurred
Business acquisition description
Number of reportable segment
Maximum percentage of sales derived from large number of customer
Percentage of drug and chemical purchases from three main suppliers
Gross profit
Segment contribution
Corporate, selling, general and administrative
Amortization of intangible assets
Operating loss
Percentage of net sales
Business acquisition of milestone payments
Net sales
Amended and Restated Certificate of Incorporation [Member]
Amended Lease Agreement [Member]
Andrew R Boll [Member]
Asset Purchase Agreement [Member]
Billing and Collection Agreement [Member]
Cantor Fitzgerald & Co [Member]
Cash and cash equivalents and Restricted cash at end of period.
Cashless Warrants Exercise [Member]
Closing price of common stock price per share.
Commercial Lease Agreement [Member]
Commission payments, percentage.
Common Stock Warrant One [Member]
Common Stock Warrants [Member]
Consultant
Consultants Employees and Directors [Member]
Convertible Note [Member]
December 31, 2017 [Member]
Deferred Acquisition Obligations, Convertible Note Payable, Stock Options, Unvested RSUs and Warrants [Member]
Dr. Lindstrom [Member]
8.00% Convertible Senior Secured Note [Member]
Elle Pharmaceutical, LLC [Member]
Employees and Consultants [Member]
Employees [Member]
Eton License Agreements [Member]
Eton Pharmaceuticals, Inc. [Member]
Eton Pharmaceuticals, Inc. One [Member]
Eton Pharmaceuticals, Inc. Two [Member]
Eton Pharmaceuticals [Member]
Exchange Agreement [Member]
Final Payment [Member]
Forfeiture factor, percentage.
General And Administrative [Member]
Imprimis TX [Member]
Initial Payment [Member]
Investments And Agreements - Related Party Transactions [Text Block]
John P Saharek [Member]
Klarity License Agreement [Member]
LSAF Loan [Member]
Lease Agreement [Member]
Lender Warrants [Member]
Lender Warrants One [Member]
License Agreement [Member]
License Revenue [Member]
Licenses [Member]
Life Sciences Alternative Funding LLC [Member]
Liquidity Disclosure [Policy Text Block]
Livernois [Member]
Loan Agreement [Member]
Loan and Security Agreement [Member]
London Inter-Bank Offered Rate [Member]
Management Services Agreement [Member]
Management Services Agreement [Member]
Non Employee Directors [Member]
Note Payable [Member]
Note Purchase Agreement [Member]
Notes Payable [Member]
Options granted to employees
Other [Member]
PIPE Investor and Placement Agent Warrants [Member]
Percentage of drug and chemical purchases from three main suppliers.
Pharmaceutical Compounding [Member]
Pharmaceutical Drug Development [Member]
Pharmacy Solutions Central, LLC [Member]
Placement Agent Warrants [Member]
Previously Authorized Shares [Member]
Product Sales, Net [Member]
Range five [member]
Range four [member].
Range one [member].
Range Six [Member]
Range three [member].
Range two [member].
Recently Adopted Accounting Pronouncements [Policy Text Block]
Reconciliation of Cash and cash equivalents.
Reconciliation Restricted cash.
Richard L. Lindstrom, M.D [Member]
Royalty payment description.
SWK Loan Agreement [Member]
SWK Warrants [Member]
Sales Agreement [Member]
Sales and Marketing Agreements [Member]
Schedule Of Prepaid Expenses and Other Current Assets [Table Text Block].
Schedule of warrants outstanding and exercisable [Table Text Block]
Second Payment [Member]
Segment contribution.
Selling And Marketing [Member]
Selling, General and Administrative [Member]
Settlement Agreement [Member]
Settlement Warrants [Member]
Share based compensation arrangement by share based payment award non options outstanding weighted average exercise price.
Share based compensation arrangements by share based payment award non options exercised in period weighted average exercise price.
Sharebased compensation arrangement by sharebased payment award non options exercisable weighted average remaining contractual term.
State Pharmacy Licenses [Member]
StockOptionPlanMember
Stock Option Plan [Member]
Stock Options [Member]
Stock Purchase Agreement [Member]
Surface License Agreements [Member]
Surface Pharmaceuticals Inc [Member]
Surface Pharmaceuticals Inc One [Member]
Surface Pharmaceuticals Inc Two [Member]
Surface Pharmaceuticals [Member]
Surface Series A Stock [Member]
Tax Reform [Member]
Third Party [Member]
2007 Incentive Stock and Awards Plan [Member]
2017 Incentive Stock and Awards Plan [Member]
unvested RSUs [Member]
Warrants expiration date.
Warrants issuance date.
Warrants Issued To Investor Relations Consultant One [Member]
Melt Pharmaceuticals [Member]
Stock issued during period for exercise of warrants.
Stock issued during period shares for exercise of warrants.
Vesting of restricted stock unit net of tax withholding.
Vesting of restricted stock unit net of tax withholding shares.
Changes in accrued property and equipment purchases.
Noncontrolling Interests.
Melt Series A Stock [Member]
Melt Pharmaceuticals, Inc. [Member]
Incremental Common Shares Attributable to Dilutive common equivalents.
Royalty payment percentage on net sales.
Finite Lived Intangible Assets Impairment.
San Diego [Member]
Irvine [Member]
Ledgewood [Member]
Operating lease percentage.
Cash paid in operating lease liability.
Finance Leases [Member]
Common Stock Warrants One [Member]
Mayfield Pharmaceuticals, Inc. [Member]
Commission expense.
May 31, 2019 [Member]
Investment in Melt Pharmaceuticals, Inc. – Related Party.
Investment in Surface Pharmaceuticals, Inc. – Related Party.
Voting rights, description.
Present value of future minimum lease payment.
Net sales of product.
Acquisition of property, plant and equipment with finance lease obligations.
Accrued litigation settlement.
Schedule of future minimum lease payments under operating lease and finance lease.
Property Available for Financing Lease [Member]
2017 Plan [Member]
Corporate, selling, general and administrative.
Percentage of net sales.
Milestone Payment [Member]
Milestone Payment [Member]
Milestone Payment [Member]
Net sales.
Amounts representing interest.
Amounts representing unamortized discount.
Current portion of capital leases.
Financing Lease [Member]
Operating Lease [Member]
ManagementServicesAgreementMember
StockOptionPlanMember
MilestonePayment2Member
MilestonePayment3Member
Assets, Current
Liabilities, Current
Cost of Goods and Services Sold
Operating Expenses
Nonoperating Income (Expense)
Income (Loss) from Equity Method Investments
Gain (Loss) on Disposition of Assets
Increase (Decrease) in Accounts Receivable
Increase (Decrease) in Inventories
Increase (Decrease) in Prepaid Expense and Other Assets
Increase (Decrease) in Employee Related Liabilities
Increase (Decrease) in Contract with Customer, Liability
Payments to Acquire Intangible Assets
Payments to Acquire Property, Plant, and Equipment
Net Cash Provided by (Used in) Investing Activities
Finance Lease, Principal Payments
Payments of Financing Costs
Repayments of Notes Payable
Net Cash Provided by (Used in) Financing Activities
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect
ReconciliationRestrictedCash
StockOption5Member
Inventory Disclosure [Text Block]
IncrementalCommonSharesAttributableDilutiveCommonEquivalents
Property, Plant and Equipment, Gross
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment
Finite-Lived Intangible Assets, Accumulated Amortization
Finite-Lived Intangible Assets, Net
Accounts Payable and Accrued Liabilities
Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year
Long-term Debt, Maturities, Repayments of Principal in Year Two
Long-term Debt, Maturities, Repayments of Principal in Year Three
Long-term Debt, Maturities, Repayments of Principal in Year Four
Long-term Debt
Interest Payable, Current
Long-term Debt, Gross
Debt Instrument, Unamortized Discount
Notes Payable
Operating Leases, Future Minimum Payments, Remainder of Fiscal Year
Operating Leases, Future Minimum Payments, Due in Two Years
Operating Leases, Future Minimum Payments, Due in Three Years
Operating Leases, Future Minimum Payments, Due in Four Years
Operating Leases, Future Minimum Payments, Due in Five Years
Operating Leases, Future Minimum Payments, Due Thereafter
Operating Leases, Future Minimum Payments Due
Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Finance Lease, Liability, Payments, Remainder of Fiscal Year
Finance Lease, Liability, Payments, Due Year Two
Finance Lease, Liability, Payments, Due Year Three
Finance Lease, Liability, Payments, Due Year Four
Finance Lease, Liability, Payments, Due Year Five
Finance Lease, Liability, Undiscounted Excess Amount
PresentValueOfFutureMinimumLeasePayment
Finance Lease, Liability, Current
Finance Lease, Liability, Payments, Due in Rolling Year Two
Finance Lease, Liability, Payments, Due in Rolling Year Three
Finance Lease, Liability, Payments, Due in Rolling Year Four
Finance Lease, Liability, Payments, Due in Rolling Year Five
Finance Lease, Liability, Payments, Due in Rolling after Year Five
Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months
Lessee, Operating Lease, Liability, Payments, Due Year Two
Lessee, Operating Lease, Liability, Payments, Due Year Three
Lessee, Operating Lease, Liability, Payments, Due Year Four
Lessee, Operating Lease, Liability, Payments, Due Year Five
Lessee, Operating Lease, Liability, Payments, Due after Year Five
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice1
Amortization
SalesRevenue